HYFT
ImmunoPrecise Antibodies Ltd.
1.40$
-4.7%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +1.2% | +3.8% | -61.7% | +8.3% | +129.6% | +13.5% | -54.7% | +30.5% | -0.8% | -0.3% | -4.5% | – | |
| – | -5.4% | +10.8% | -56.3% | -10.5% | +118.0% | -11.7% | -35.2% | -10.5% | +14.0% | -3.6% | +0.4% | – | |
| – | +8.2% | -2.8% | -67.5% | +35.5% | +140.7% | +35.4% | -65.8% | +74.3% | -8.9% | +2.0% | -7.8% | – | |
| – | +19.9% | -7.4% | +60.6% | -32.4% | +5.1% | +3.0% | -3.7% | +16.8% | -2.5% | +30.4% | -16.2% | – | |
| – | +26.3% | -1.4% | -18.6% | -14.9% | +25.9% | +3.1% | -11.1% | -6.7% | +60.2% | +6.7% | +35.0% | – | |
| – | +29.1% | +1.3% | -13.3% | -5.6% | +21.5% | -10.2% | -4.0% | -4.5% | +11.3% | +12.0% | +25.7% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -1.8% | -19.0% | -49.7% | +50.9% | +1.8% | -37.5% | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | -134.9% | – | -170.8% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.